Mycenax Biotech Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 652.62 million compared to TWD 732.28 million a year ago. Net loss was TWD 682.85 million compared to TWD 453.63 million a year ago.

Basic loss per share from continuing operations was TWD 3.32 compared to TWD 2.74 a year ago. Diluted loss per share from continuing operations was TWD 3.32 compared to TWD 2.74 a year ago.